Streptozocin-Diabetes Modifies Acetylcholine Release from Mouse Phrenic Nerve Terminal and Presynaptic Sensitivity to Succinylcholine

Ikuko Kimura, Mari Okazaki and Masayasu Kimura

Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930–01, Japan

Received September 7, 1992 Accepted January 25, 1993

ABSTRACT—Acetylcholine (ACh) release from the motor nerve terminal in the streptozocin-induced diabetic state was studied in mouse phrenic nerve-diaphragm muscle preparations. Electrically evoked release of 3H-ACh from the preparation preloaded with 3H-choline was measured during two consecutive periods of stimulation (S1 and S2). In diabetic mice, the amount of 3H-ACh release during S2 was decreased, and the evoked ACh release declined more steeply with successive stimulation periods than in normal ddY mice. The decrease in release was restored when the presynaptic autoreceptors were stimulated by accumulating ACh under the irreversible inhibition of junctional cholinesterase by methanesulfonyl fluoride. This effect was abolished by the administration of (+)-tubocurarine (5 μM). In diabetic mice, the biphasic (acceleration and suppression) effect by succinylcholine on evoked ACh release was caused at 3- to 10-fold lower concentrations than in normal mice. The degree of enhancement of resting 3H-overflow by succinylcholine (10 and 30 μM) was greater in the diabetic state. These results indicated that in the diabetic state, the decrease in evoked ACh release interferes with its presynaptic action on inducing further release (positive feedback modulation) via the presynaptic nicotinic ACh receptor (n-AChR). The presynaptic hypersensitivity to succinylcholine may be due to the augmentation of presynaptic n-AChR sensitivity caused by the reduction of evoked ACh release in the diabetic state.

Keywords: Acetylcholine release (evoked, resting), Succinylcholine, Nicotinic acetylcholine receptor (presynaptic), Phrenic nerve-diaphragm muscle (mouse), Streptozocin-diabetes

Diabetic neuropathy, a disorder of peripheral nerves particularly, is one of the most common complications of diabetes mellitus. Nerve conduction velocity is reduced in diabetic peripheral neurons, and pathogenetic mechanisms responsible for the impairment of axons and Schwann cells have been investigated (1). Few studies have examined whether the diabetic state affects transmitter release from motor nerve terminals.

Electrophysiological and mechanical studies showed that diabetes causes functional changes in neuromuscular transmission (2, 3). Succinylcholine is hypersensitive at the neuromuscular junction in the diabetic state (4, 5), and the hypersensitivity is mainly attributed to the diabetic skeletal muscle cells (6, 7). The change in presynaptic sensitivity to succinylcholine in diabetes has not yet been studied with regard to the abnormalities of presynaptic function associated with diabetic neuropathy. We have previously reported that succinylcholine affected nerve-

evoked acetylcholine (ACh) release from the phrenic nerve terminal of normal ddY mice through presynaptic nicotinic receptors (8). The present study was designed to evaluate the change of ACh release and the sensitivity of nerve terminal to succinylcholine in the streptozocin (STZ)-induced diabetic state by the 3H-efflux counting method and radioimmunoassay using mouse phrenic nerve-hemidiaphragm muscle preparations.

MATERIALS AND METHODS

Male ddY mice were used after 4–5 weeks of diabetes (8- to 9-week-old, 27.5–36.5 g body weight, blood glucose level: 19.4–37.0 mM) induced by the administration of 150 mg/kg STZ, which was dissolved in 0.9% NaCl and injected into the tail veins of the mice. Normal male ddY mice (7- to 10-week-old, 31–41 g body weight, blood glucose level: 5.8–7.3 mM) were used as the controls. Blood
glucose levels were measured by the glucose oxidase method with a glucose analyzer (Type II, Beckman, Fullerton, CA, USA).

The mouse was killed by decapitation. The right or left phrenic nerve-diaphragm muscle was isolated as previously reported (8) and then suspended in a 2-ml chamber containing Krebs’ solution gassed with a mixture of 95% O₂ and 5% CO₂ at 37°C. Krebs solution was composed of 113 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl₂, 1.2 mM MgSO₄, 25 mM NaHCO₃, 1.2 mM KH₂PO₄, and 11.5 mM glucose.

Measurement of ³H-ACh in the perfusate

The above preparation was incubated for 60 min in 2-ml Krebs solution containing methyl-³H-choline. The preparation was stimulated for 40 min with trains of pulses, as described below, and allowed to rest for the next 20 min. After the incubation period, the preparation was then washed with Krebs solution at a rate of 2 ml/min for 60 min to remove excess ³H-choline. The perfusion rate was then slowed to 1 ml/min, and the phrenic nerve was stimulated electrically for 3 min, four times starting at 8 (S₀), 32 (S₁), 56 (S₂) and 80 (S₃) min after the end of the washout period. Trains of 40 pulses (50 Hz, 0.2 msec duration, for 0.8 sec) were applied to the phrenic nerve every 10 sec for 3 min by supramaximal square pulses through a pair of platinum electrodes (1–10 V). Samples were collected every min from 9 min before the 32-min point (S₁).

Radioactivity of the samples was measured by a scintillation beta spectrometer (LS 3801, Beckman). The stimulation-induced increase in tritium release was calculated by subtracting the mean of the basal release from the total release. Mean basal release was calculated from six data before and after a stimulation period. The effects of drugs on the evoked release of ACh were detected by changes in the S₂/S₁ ratios.

The effect of succinylcholine on basal tritium efflux was examined by calculating the ratio of tritium radioactivity of 10-min samples collected after the addition of succinylcholine (B₂) to that of samples collected before the addition (B₁). In the control experiments, the B₂/B₁ ratio was also obtained in the absence of succinylcholine because it shows high cross-reactivity to succinylcholine.

Separation of ³H-choline and ³H-ACh

The ³H-choline and ³H-ACh fractions were separated in each perfusate by a modified choline kinase method (9). Each 500-μl aliquot of perfusate was treated for 15 min with 20 μl of choline kinase (10 μM U/ml) in the presence of 125 μl of sodium phosphate buffer (pH 8.0), 50 μl of 10 mM ATP and MgCl₂. Choline kinase converts ³H-choline to ³H-phosphorylcholine. The mixture of ³H-ACh and ³H-phosphorylcholine was then separated by stirring with 1 ml 3-heptanone containing 30 mM tetraphenylborate. ³H-Phosphorylcholine remained in the aqueous phase under these conditions, but ³H-ACh was distributed quantitatively into the upper 3-heptanone phase. A portion of the 3-heptanone phase was transferred to a tube containing 800 μl in 1 N HCl and mixed, and then the radioactivity of tritium in the HCl phase was measured as ³H-ACh.

Radioimmunoassay for ACh in the perfusate

The absolute amount of spontaneous and electrically evoked ACh release from the preparation was determined in part by radioimmunoassay (8, 10, 11) with ACh-antiserum. The experimental protocol was the same as that described above except for the incubation with ³H-choline. The preparation was treated with 10 mM methanesulfonfyl fluoride (MSF), an irreversible cholinesterase inhibitor, during the incubation period to prevent hydrolysis of ACh. The perfusate was collected continuously on ice. Then 630 μl of perfusate was incubated for 17 hr with 100 μl of diluted antiserum (1:300) in Tris-HCl buffer (0.1 M, pH 7.4) containing 0.4% bovine gamma-globulin, 0.05% diisopropylfluorophosphate, 10 μl of 10 mM acetic acid and 60 μl of ³H-ACh (4.8 pg, 5500 dpm). The same volume of Krebs solution was used for a blank test. After removing free ³H-ACh by the ammonium sulfate method, antibody-bound ACh was measured in the liquid scintillation beta counter. ACh-antiserum cannot be used to determine the presynaptic effect of succinylcholine because it shows high cross-reactivity to succinylcholine.

Peak amplitude of tetanic tension

The isometric contractions were measured with a force displacement transducer (SB1T, Nihon Kohden, Tokyo) and recorded (Linea Recorder, WR3701, Graphtec, Tokyo). The resting tension of 500 mg was loaded in each preparation. The effects of drugs on the peak amplitude of tetanic tension were represented as T₂/T₁, where T was an averaged value of the 6th, 12th and 18th peak amplitude of tetanic tension for a 3-min stimulation period. T₁ and T₂ were produced by the S₁ and S₂ stimulation periods, respectively.

Statistics

Statistical significances of the differences were analyzed by the unpaired Student’s t-test. P < 0.05 was adopted as the level of significance.

Drugs

Methyl-³H-choline chloride (555 GBq/mmol), acetyl-methyl-³H-choline chloride (2.78 TBq/mmol) (Amersham, Buckinghamshire, England), succinylcholine chloride 2H₂O, gamma-globulin bovine Cohn fraction II, III,
streptozocin, choline kinase (Sigma, St. Louis, MO, USA), acetylcholine chloride (Daichi Seiyaku, Tokyo) and methanesulfonyl fluoride, 3-heptanone (Aldrich, Milwaukee, WI, USA) and sodium tetraphenylborate (Wako, Osaka) were used. Rabbit ACh-antiserum (NGC-10 880902, sensitivity of 10 pg/tube) was a gift from Prof. K. Kawashima (Department of Pharmacology, Kyoritsu College of Pharmacy, Japan).

RESULTS

Decrease in evoked ACh release by successive electrical stimulation periods in the diabetic state

Electrically evoked $^3$H-ACh release over the level of spontaneous output from the phrenic nerve-diaphragm muscle preparation of STZ diabetic mice was determined by measuring the overflow of tritium (Table 1). The release of radioactivity at rest before $S_1$ was 3212.4±248.1 dpm/min (n=8) in diabetic mice, which was not different from 3520±232.3 dpm/min (n=10) in normal mice. In the $^3$H-efflux counting method, the amount of evoked $^3$H-ACh release declined with successive stimulation periods. The time-dependent decline of release is due to the diminution of preloaded $^3$H-choline. The amount of $^3$H-ACh release evoked by the $S_2$-stimulation period was significantly reduced in diabetic mice, whereas that evoked by $S_1$ was unchanged, and the $S_2/S_1$ ratio was smaller in diabetic mice than in normal ones. The release from preparations pretreated with MSF, an irreversible cholinesterase inhibitor, was the same in the diabetic state as in the normal state. (+)-Tubocurarine at 5 $\mu$M, which had no effect on ACh release, abolished the MSF treatment-induced enhancement of $^3$H-ACh release evoked by $S_1$ in the diabetic state.

The radioimmunoassay using MSF also showed that the absolute values of evoked ACh release were constant through two stimulation periods both in normal and diabetic mice and tended to be increased in the diabetic neuromuscular junction (Table 2). Resting ACh release from diabetic preparations was about 2.5-fold larger than that from normal ones.

| Table 1. Electrically evoked acetylcholine release from normal and streptozocin (STZ)-diabetic mouse phrenic nerve-diaphragm muscle preparation determined by $^3$H-efflux counting method |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| S1 | S2 | S2/S1 | 5 $\mu$M d-TC |
|-----------------|-----------------|-----------------|-----------------|
| Normal ddY | 671±51 | 475±50 | 0.70±0.02 | 0.64±0.07 |
| MSF treatment | 484±89 | 391±120 | ** | 0.62±0.07 |
| STZ 4–5-week-elapsed | 479±92 | 227±48 | 0.48±0.04 | 0.36±0.11 |
| MSF treatment | 531±61 | 390±37 | 0.74±0.01 | 0.48±0.03 |

Methanesulfonyl fluoride (10 mM, MSF) was administered during the 60-min incubation period. Electrically evoked release ($S_1$, $S_2$) for 3 min starting after the 32nd and 56th min of collection was calculated by subtracting spontaneous release from the total release. (+)-Tubocurarine (5 $\mu$M, d-TC) was administered 10 min before $S_2$. Values are means±S.E. (n=3–6). The significance of differences was analyzed by Student’s t-test. **P<0.01. *P<0.01, significantly different from the value without d-TC.

| Table 2. Resting and electrically evoked acetylcholine release from normal and streptozocin (STZ)-diabetic mouse phrenic nerve-diaphragm muscle preparation determined by radioimmunoassay |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Resting release | Evoked release |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| B | S1 | S2 | S2/S1 |
|-----------------|-----------------|-----------------|-----------------|
| Normal ddY | 67.8±6.0 | 104.9±19.6 | 133.6±12.8 | 1.37±0.15 |
| STZ 4–5-week-elapsed | 177.8±33.8 | 175.0±34.4 | 188.5±27.7 | 1.13±0.16 |

Methanesulfonyl fluoride was administered during the 60-min incubation period. Electrically evoked release ($S_1$, $S_2$) for 3 min starting after the 32nd and 56th min of collection was calculated by subtracting the resting release (B, the mean of basal release) from the total release. Values are means±S.E. (n=3–5). The significance of difference was analyzed by Student’s t-test. *P<0.05.
The effect of succinylcholine on evoked ACh release and peak tetanic tension in the diabetic state

The concentration-response curves of succinylcholine for the ratios of evoked ACh release ($S_2/S_1$) and peak amplitude of tetanic tension ($T_2/T_1$) shows biphasic patterns (Fig. 1), like in the normal state as previously reported (8). Succinylcholine (0.1 - 10 µM) enhances ACh release and peak tetanic tension at low concentrations, but reduces them at high concentrations. The IC_{50} (95% confidence limit) for $S_2/S_1$ and $T_2/T_1$ were 1.9 µM (1.1 - 3.3) and 3.3 µM (2.3 - 4.7), respectively.

Effects of succinylcholine on basal tritium overflow in the diabetic state

$B_2/B_1$ (the ratio of basal release) without succinylcholine was 0.88±0.01 in the normal mice (n=10) and 0.88±0.02 in the diabetic mice (n=8). Figure 2 shows typical data of the increasing effect of succinylcholine (10 µM) on basal tritium release. Succinylcholine increased the $B_2/B_1$ ratio in a concentration-dependent manner in both states (Fig. 3). The effect caused by 10 and 30 µM succinylcholine was significantly greater in diabetic mice than in normal ones.

The spontaneous release of tritium enhanced by succinylcholine was separated into $^3$H-choline and $^3$H-ACh by the modified choline kinase method. Both the overflow of $^3$H-choline and $^3$H-ACh were increased spontaneously by succinylcholine, whereas only $^3$H-ACh release was evoked by electrical nerve stimulation (Fig. 4). The ratio of $^3$H-ACh release to total tritium release spontaneously induced by 30 µM succinylcholine was compared between normal and diabetic preparations. The two ratios (normal: 0.53±0.01, and diabetic: 0.45±0.04, n=3) were not significantly different from each other.

![Fig. 1. Concentration-response curves of succinylcholine (SuCh) for evoked $^3$H-ACh release (closed symbols) and peak amplitude of tetanic tension (open symbols) in streptozocin (STZ)-induced diabetic mouse phrenic nerve-muscle preparations. Succinylcholine was administered at various concentrations 10 min before $S_2$. Each point represents the mean value for relative ratios of ACh release ($S_2/S_1$) and tension ($T_2/T_1$), and vertical lines represent S.E. (n=4 - 6). The significance of differences from controls (without drug) was analyzed by Student's $t$-test. **$P<0.01$ and *$P<0.05$.](image)

![Fig. 2. Typical data showing the effects of succinylcholine (SuCh) (10 µM) on the release of tritium radioactivity from normal (upper) and streptozocin (STZ)-induced diabetic (lower) mouse hemidiaphragm preparations. Periods of stimulation (50 Hz, trains of 40 shocks) were applied every 10 sec as indicated by the open columns. The shaded columns indicate the presence of succinylcholine. The horizontal axis indicates the time after the end of the washout period.](image)

![Fig. 3. Effect of succinylcholine (SuCh) on basal $^3$H-overflow ($B_2/B_1$ ratio) from normal (open symbols) and streptozocin (STZ) induced diabetic (closed symbols) mouse hemidiaphragm preparations. $B_1$ and $B_2$ are the total values of 10 min-samples collected before and after the addition of succinylcholine, respectively. Each point represents the mean value (n = 3 - 10) and vertical lines indicate S.E. The significance of differences from controls (normal ddY mice) was analyzed by Student's $t$-test. *$P<0.05$.](image)
Fig. 4. Typical data showing the effects of succinylcholine (SuCh, 30 μM) on the overflow of 3H-choline (upper line) and 3H-acetylcholine (ACh) (lower line). Radioactive choline and ACh in the perfusate were separated by the modified choline kinase method. Periods of stimulation (50 Hz, trains of 40 shocks) were applied every 10 sec as indicated by the open column. The shaded column indicates the presence of succinylcholine. The horizontal axis indicates the time after the end of the washout period.

DISCUSSION

The abnormalities of neuromuscular transmission and the changes in sensitivity of the neuromuscular junction to various muscle relaxants in the diabetic state have been investigated. Schofield et al. (12) have demonstrated that phrenic nerve-diaphragm muscle preparations from alloxan-diabetic rats show reduced sensitivity to the neuromuscular blocking effect of (+)-tubocurarine, but no change is observed with decamethonium, a depolarizing neuromuscular blocker. However, our data do not agree with their data, because we (5) have observed that in situ sciatic nerve-gastrocnemius muscle preparations of alloxan diabetic mice and genetically diabetic male KK-CA mice are hypersensitive to succinylcholine in the twitch-blocking effect. Furthermore, succinylcholine reduces the amplitude of ACh potential at lower concentrations in diaphragm muscles from diabetic KK-CA mice than normal mice. These data suggest that the postsynapse or the muscle cells themselves are hypersensitive to succinylcholine. Our present study demonstrates that diabetes rendered the presynapse also more sensitive to succinylcholine. We previously reported that succinylcholine (0.3–30 μM) shows a biphasic effect to both evoked ACh release and peak tetanic tension: acceleration at low concentrations and suppression at high concentrations (IC50 of S2/S1: 14.6 μM, T2/T1: 7.1 μM) (8). The diabetic state shifted the curves of both release and tension 3- to 10-fold to the left and diminished the extent of enhancement of evoked ACh release at the low concentration of succinylcholine (Fig. 1). Succinylcholine induced the inhibition of evoked ACh release 7.7-fold more potently in diabetic mice than in normal ones. Since succinylcholine affects ACh release through presynaptic nicotinic ACh receptor (n-AChR) (8), this result suggests that the susceptibility to succinylcholine of presynaptic n-AChR is increased in the diabetic state.

Succinylcholine increased basal tritium overflow in the resting state (Figs. 2 and 3). It is reported that carbamylcholine causes an increase in the frequency of the miniature end-plate potential along with a postsynaptic block in rat hemidiaphragm preparation (13). The frequency is augmented by depolarization of the nerve terminal (13, 14). Since motor nerves have nicotinic receptors that mediate membrane depolarization (15, 16), succinylcholine may depolarize the nerve terminals through these receptors and increase basal tritium overflow. In diabetic mice, the absolute amount of resting ACh release measured by radioimmunoassay (Table 2) and the extent of enhancement of resting tritium release induced by high concentrations of succinylcholine (Fig. 3) were greater than in normal mice. An electrophysiological study has shown that ACh is released mainly in a nonquantal manner at rest, whereas quantal release also occurred spontaneously, generating miniature end-plate potential (17). The nonquantal ACh leakage from the motor nerve terminal is increased by ouabain, a Na+,K+-ATPase inhibitor (18). The activity of Na+,K+-ATPase is reduced in diabetic neurons (19, 20), which may cause an increase of ACh release in the resting state. The hyperresponse to succinylcholine in resting release may be due to the depolarization of diabetic nerve terminals caused by reduction of the enzyme activity and/or increase of nonquantal ACh release. Succinylcholine increased the overflow of 3H-choline in addition to that of 3H-ACh (Fig. 4), whereas electrical nerve stimulation or high K+ solution (21) causes selective liberation of 3H-ACh but not 3H-choline. Diabetes enhanced succinylcholine-induced spontaneous overflow of both ACh and choline to the similar extent. The source and mechanism of choline liberation remains uncertain.

The mouse hemidiaphragm preparations synthesize 3H-ACh from 3H-choline taken up during the incubation period. The newly synthesized 3H-ACh is selectively released from the phrenic nerve terminal by electrical nerve stimulation. In diabetic mice, the amount of tritium release was reduced by repeated stimulation periods, whereas that during S1 was unchanged (Table 1). This result suggests that ACh release induced by tetanic nerve stimulation is easily decreased in diabetic nerves. Low concentrations of succinylcholine enhanced evoked 3H-ACh release to smaller extent in the diabetic state (Fig. 1) than in the normal state (8). Therefore, the number of releasable vesicles may be reduced in the diabetic nerve terminal. The reduced amount of ACh release caused by suc-
cessive stimulation periods in the diabetic state was restored by pretreatment with MSF. Inhibition of tissue cholinesterase raised the concentration of endogenously released ACh in the synaptic cleft, and then intensified the effect of ACh on presynaptic autoreceptors. Evidence has been obtained that ACh enhances its own release from motor nerve terminals through presynaptic nicotinic receptors during high frequency nerve stimulation (22–24). The nicotinic positive feedback mechanism is physiologically predominant over other feedback modulations to retain ACh release during high frequency stimulation (25). In diabetic motor nerve terminals, the nicotinic positive feedback mechanism could not operate effectively because of the reduction of evoked ACh release. (+)-Tubocurarine completely inhibited the effect of MSF treatment, supporting the above explanation (Table 1). The release was unchanged with MSF treatment in normal mice; the susceptibility of facilitatory nicotinic autoreceptors is relatively higher than other inhibitory receptors in diabetic motor nerve terminals. In the neuromuscular junction, nerve impulse-evoked ACh release from motor nerve terminals influence muscle activity. Denervation of adult skeletal muscle increase the sensitivity to ACh in extra-junctional regions of the muscle fiber and increases n-AChR mRNA levels (26, 27). The reduction in evoked ACh release induced by the diabetic state may lead to an increase in the number of n-AChR in nerve terminals.

In conclusion, the diabetic state reduced evoked ACh release and increased resting release. The evoked/resting release ratio was lower in the diabetic state than in the normal state. In the diabetic state, the sensitivity of the motor nerve terminal containing presynaptic n-AChR to succinylcholine was increased. The hypersensitivity of the presynaptic response to succinylcholine may be due to augmentation of the sensitivity of presynaptic n-AChR in the diabetic state.

Acknowledgments

We are grateful to Prof. K. Kawashima (Department of Pharmacology, Kyoritsu College of Pharmacy) for his kind gift of ACh antiserum and for his valuable advice.

REFERENCES

1 Clements, R.S., Jr.: Diabetic neuropathy—new concepts of its etiology. Diabetes 28, 604–611 (1979)
2 Miglietta, O.: Neuromuscular junction defect in diabetes. Diabetes 22, 719–723 (1973)
3 Schiller, Y. and Rahamimoff, R.: Neuromuscular transmission in diabetes: response to high-frequency activation. J. Neurosci. 9, 3709–3719 (1989)
4 Minker, E., Phan, Kac. and Kolta, M.: Effect of muscle relaxants on the motor endplate of diabetic and glucocorticoid pretreated rats. Acta Physiol. Hung. 67, 257–266 (1986)
5 Kimura, M., Kimura, I., Nojima, H. and Murol, M.: Diabetes mellitus-induced hypersensitivity of mouse skeletal muscles to acetylcholine and succinylcholine. Japan. J. Pharmacol. 40, 251–256 (1986)
6 Fujihara, M., Kimura, I., Nakamura, T. and Kimura, M.: Developmentally delayed sensitivity of acetylcholine receptor in myotubes of nerve-muscle cocultures from genetically diabetic mouse embryos. J. Pharmacobiodyn. 9, 402–408 (1986)
7 Kimura, M., Fujihara, M., Nojima, H. and Kimura, I.: Hypersensitivity of acetylcholine receptor in diabetic skeletal muscle to neuromuscular blockers: the effect on myotubes cultured with spinal cord or its extract. J. Pharmacobiodyn. 9, 29–38 (1986)
8 Kimura, I., Okazaki, M., Uwano, T., Kobayashi, S. and Kimura, M.: Succinylcholine-induced acceleration and suppression of electrically evoked acetylcholine release from mouse phrenic nerve-hemidiaphragm muscle preparation. Japan. J. Pharmacol. 57, 397–403 (1991)
9 McGee, R., Jr., Smith, C., Christian, C., Mata, M., Nelson, P. and Nirenberg, M.: A new capillary tube system for measuring the uptake and release of materials from cultured cells. Anal. Biochem. 101, 320–326 (1980)
10 Kawashima, K., Ishikawa, H. and Mochizuki, M.: Radioimmunoassay for acetylcholine in the rat brain. J. Pharmacol. Methods 3, 115–123 (1980)
11 Kawashima, K., Fujimoto, K., Suzuki, T. and Oohata, H.: Direct determination of acetylcholine release by radioimmunoassay and presence of presynaptic M1 muscarinic receptors in guinea pig ileum. J. Pharmacol. Exp. Ther. 244, 1036–1039 (1988)
12 Schofield, G.G., Furman, B.L. and Marshall, I.G.: The effect of acute alloxan diabetes on the sensitivity of the rat skeletal neuromuscular junction to drugs. Acta Diabetol. Latina 15, 287–293 (1978)
13 Miyamoto, M.D. and Volle R.L.: Enhancement by carbachol of transmitter release from motor nerve terminals. Proc. Natl. Acad. Sci. U.S.A. 71, 1489–1492 (1974)
14 Liley, A.W.: The effects of presynaptic polarization on the spontaneous activity at the mammalian neuromuscular junction. J. Physiol. (Lond.) 134, 427–443 (1956)
15 Hubbard, J.I., Schmidt, R.F. and Yokota, T.: The effect of acetylcholine upon mammalian motor nerve terminals. J. Physiol. (Lond.) 181, 810–829 (1965)
16 Chang, C.C. and Hong, S.J.: A regenerating release of acetylcholine from mouse motor nerve terminals treated with anticholinesterase agents. Neurosci. Lett. 69, 203–207 (1986)
17 Vizi, E.S. and Vyskocil, F.: Changes in total and quantal release of acetylcholine in the mouse diaphragm during activation and inhibition of membrane ATPase. J. Physiol. (Lond.) 286, 1–14 (1979)
18 Vyskocil, F. and Illes, P.: Non-quantal release of transmitter at mouse neuromuscular junction and its dependence on the activity of Na+-K+ ATPase. Pflugers Arch. 370, 295–297 (1977)
19 Greene, D.A. and Lattimer, S.A.: Impaired energy utilization and Na-K-ATPase in diabetic peripheral nerve. Am. J. Physiol. 246, E311–E318 (1984)
20 Kjeldsen, K., Brøndgaard, H., Sidenius, P., Larsen, J.S. and Nergaard, A.: Diabetes decreases Na+-K+ pump concentration in skeletal muscles, heart ventricular muscle, and peripheral nerves of rat. Diabetes 36, 842–848 (1987)
21 Wessler, I. and Steinlein, O.: Differential release of [3H]acetyl-
choline from the rat phrenic nerve-hemidiaphragm preparation by electrical nerve stimulation and by high potassium. Neuroscience 22, 289–299 (1987)

22 Gibb, A.J. and Marshall, I.G.: Pre- and post-junctional effects of tubocurarine and other nicotinic antagonists during repetitive stimulation in the rat. J. Physiol. (Lond.) 351, 275–297 (1984)

23 Bowman, W.C. and Webb, S.N.: Tetanic fade during partial transmission failure produced by non-depolarizing neuromuscular blocking drugs in the cat. Clin. Exp. Pharmacol. Physiol. 3, 545–555 (1976)

24 Wessler, I., Halank, M., Rasbach, J. and Kilbinger, H.: Presynaptic nicotine receptors mediating a positive feedback on transmitter release from the rat phrenic nerve. Naunyn Schmiedebergs Arch. Pharmacol. 334, 365–372 (1986)

25 Bowman, W.C.: Pharmacological manipulation of prejunctional events. In Pharmacology of Neuromuscular Function. pp. 84–99, Butterworth & Co., Ltd., London (1990)

26 Witzemann, V., Barg, B., Nishikawa, Y., Sakmann, B. and Numa, S.: Differential regulation of muscle acetylcholine receptor γ- and ε-subunit mRNAs. FEBS Lett. 223, 104–112 (1987)

27 Goldman, D., Brenner, H.R. and Heinemann, S.: Acetylcholine receptor α-, β-, γ-, and δ-subunit mRNA levels are regulated by muscle activity. Neuron 1, 329–333 (1988)